NeuroVive to present at 2nd Annual H.C. Wainwright NASH Investor Conference

Lund, Sweden, 16 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its Chief Medical Officer Magnus Hansson will present the company’s non-alcoholic steatohepatitis (NASH) programs NV556 and NVP022 at the 2nd Annual H.C. Wainwright NASH Investor Conference on 19 March 2018 at 11:20 a.m. EDT (4:20 p.m CET) at the St. Regis Hotel in New York.

Neurovive’s NASH programs have been recognized as having high potential and the company has been selected to present at the prestigious H.C. Wainwright NASH Investor Conference. The second edition of the conference gathers investors together with biotech, pharmaceutical and diagnostic companies active in the NASH therapeutic development field, as well as renowned NASH opinion leaders.

A live webcast of the presentation will be available here:

About NV556

NV556 is a drug candidate with a directly acting antifibrotic mechanism of action targeting NASH patients who have progressed from the initial metabolic stage characterized by fat storage and inflammation. NV556 is a potent cyclophilin inhibitor derived from NeuroVive’s Sangamide class of compounds. NV556 has undergone extensive preclinical development, has favorable drug-like properties and confirmed antifibrotic effect in the experimental STAM and MCD NASH models. The company has accelerated its NV556 out-licensing activities with the aim of reaching a partnership agreement during 2018.

About NVP022

NVP022 targets the metabolic components of NASH by using mild, liver-targeted protonophores to uncouple energy-linked functions and increase energy expenditure in the liver. This removes excess fat storage and thereby counteracts the pathophysiological processes in NASH. NeuroVive is currently evaluating lead compounds with the expectation to select a candidate drug during 2018.

About NASH

Hepatic fat storage, inflammation and fibrosis are symptoms of NASH – a condition that can lead to cirrhosis of the liver and liver cancer (hepatocellular carcinoma). An estimated 20% of the world population suffers from nonalcoholic fatty liver disease (NAFLD) and 20 % of the NAFLD population have non-alcoholic steatohepatitis (NASH). A strong link between NASH and several other metabolic disorders, such as diabetes and obesity, exists. There are currently no registered treatments for NASH, but with treatments reaching the global market, the NASH market is expected to exceed USD 25 billion by 2026.

The information was submitted for publication, through the agency of the contact person set out below, at 11:00 a.m. CET on 16 March 2018.

For more information please contact:

Daniel Schale, Director of Communications

+46 (0)46-275 62 21,

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard),

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. For NeuroVive’s projects aimed at larger therapeutic areas with high potential, the strategy is outlicensing in the pre-clinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).